miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1

By Jinhong Chang, E. Nicolas, Debora Marks, Christopher Sander, A. Lerro, M. Buendia, Chunxiao Xu, W. Mason, T. Moloshok, R. Bort and 2 more. RNA Biology, 2004

817 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/43bc8ca5fcdf5799cd9abc0d007acabe6b6f41bf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma (2011, background): “For example, the liver-specific miRNA miR-122 (27) was detected only in the protein-associated fractions, suggesting that hepatocytes may release miR-122 through a protein carrier pathway.”
Regulating gene expression through RNA nuclear retention. (2005, background): “In cells expressing mCAT2, the mCAT1 transcript is degraded by miRNAs (miR-122), suggesting that a critical balance is required for maintaining cellular homeostasis (Chang et al., 2004).”
Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties (2009, neutral): “The temporal expression pattern of miR-122 during liver development is consistent with its involvement in liver differentiation (Chang et al., 2004).”
MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. (2012, neutral): “MicroRNA 122 (miR-122) is a dominant hepatocyte-specific miRNA (1, 4).”
Circulating microRNAs, potential biomarkers for drug-induced liver injury (2009, background): “In contrast, some of the affected circulating miRNAs by acetaminophen overdosing, as demonstrated in our study, are highly restricted to the liver, such as mir-122 (32).”
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. (2012, neutral): “A significant increase in the expression of known targets such as Aldoa , Slc7a1 , Cs , and Ccng1 (3, 13) confirmed functional depletion of miR-122 in LKO livers (Supplemental Figure 2B).”
Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas (2006, background): “Among HCCs cell lines miR-122 was not detectable in human (HepG2, Hep3B) or mouse (Hepa) cells and expressed at a significantly low-level in human (H-7) [Chang et al., 2004] and rat (H4) cells compared to the liver (data not shown).”
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME (2013, neutral): “It could be demonstrated that miR-122 is most abundantly expressed in the liver, accounting for approximately 70 % of all hepatic miRNA (Chang et al. 2004; Orom et al. 2008).”
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/β-secretase expression (2008, methodology): “We used the prediction algorithms miRanda (22), Targetscan (23, 24), Pictar (25), and miRbase (26) to identify AD-related potential target genes for these miRNAs.”
microRNA-122 stimulates translation of hepatitis C virus RNA (2008, background): “However, until now miR-122 was found to be expressed almost exclusively in liver cells and in the hepatoma cell line Huh-7 (Lagos-Quintana et al, 2002; Sempere et al, 2004; Chang et al, 2005; Fu et al, 2005).”
miR-221 overexpression contributes to liver tumorigenesis (2009, background): “Among the five miRNAs up-regulated 2- to 3-fold in cases of β-catenin gene mutation was miR-34a, known previously as a p53 target, and miR-122, the miRNA most highly expressed in hepatocytes (6, 7).”
MicroRNAs in development and disease. (2011, background): “In addition, miR-122 is also responsible for almost complete suppression of the cationic amino acid transporter in the adult liver (84).”